Granted Patent
B2
US 12,421,303 · App. 17/109,028 · Granted Sep 23, 2025
Agents, uses and methods for the treatment of synucleinopathy
Inventors:
Pekka Kallunki (Valby, DK); Paul E. G. Kristjansen (Valby, DK); Jeffrey B Stavenhagen (Valby, DK)
Assignee:
H. Lundbeck A/S
C07K16/18A61K31/197A61K39/395A61K39/3955A61K45/06A61P25/16A61P25/28A61K2039/505A61K2039/507A61K2039/545C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.
Claims (65)
1. A method of treating Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson's disease, and multiple system atrophy in a subject, said method comprising administering
(I) a monoclonal antibody or antigen-binding fragment thereof comprising:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(ii) a Heavy Chain CDR2 having the amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO:33, SEQ ID NO:34, or SEQ ID NO:35;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6; or
(II) a monoclonal antibody or antigen-binding fragment thereof comprising:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:20;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:21;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:22;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:23;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:24; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:25; and
an additional medicament.
2. The method according to claim 1 , wherein the treatment is chronic.
3. The method according to claim 2 , wherein the chronic treatment is for at least 2 weeks.
4. The method according to claim 1 , wherein the subject is human.
5. The method or use according to claim 1 wherein said monoclonal antibody and additional medicament are administered approximately simultaneously or wherein the medicaments are taken separately.
6. The method according to claim 1 , wherein the antibody or a fragment thereof, comprises:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:2;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6.
7. The method according to claim 6 , wherein the antibody comprises the heavy chain variable domain of SEQ ID NO:7 or the light chain variable domain of SEQ ID NO:8.
8. The method according to claim 7 , wherein the antibody comprises a heavy chain consisting of a variable domain of SEQ ID NO:7 and a light chain consisting of a variable domain of SEQ ID NO:8.
9. The method according to claim 1 , wherein the antibody or a fragment thereof, comprises:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:33;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6.
10. The method according to claim 9 , wherein the antibody comprises the heavy chain variable domain of SEQ ID NO:30 or the light chain variable domain of SEQ ID NO: 8.
11. The method according to claim 10 , wherein the antibody comprises a heavy chain consisting of a variable domain of SEQ ID NO:30 and a light chain consisting of a variable domain of SEQ ID NO:8.
12. The method according to claim 1 , wherein the antibody or a fragment thereof, comprises:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:34;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6.
13. The method according to claim 12 , wherein the antibody comprises the heavy chain variable domain of SEQ ID NO:31 or the light chain variable domain of SEQ ID NO: 8.
14. The method according to claim 13 , wherein the antibody comprises a heavy chain consisting of a variable domain of SEQ ID NO:31 and a variable domain of SEQ ID NO: 8.
15. The method according to claim 1 , wherein the antibody or a fragment thereof, comprises:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:35;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:6.
16. The method according to claim 15 , wherein the antibody comprises the heavy chain variable domain of SEQ ID NO:32 or the light chain variable domain of SEQ ID NO: 8.
17. The method according to claim 16 , wherein the antibody comprises a heavy chain consisting of a variable domain of SEQ ID NO:32 and a variable domain of SEQ ID NO: 8.
18. The method according to claim 1 , wherein the antibody or a fragment thereof, comprises:
(i) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:20;
(ii) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:21;
(iii) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:22;
(iv) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:23;
(v) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:24; and
(vi) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:25.
19. The method according to claim 18 , wherein the antibody comprises a heavy chain variable domain of SEQ ID NO:26 or the light chain variable domain of SEQ ID NO: 27.
20. The method according to claim 19 , wherein the antibody comprises a heavy chain consisting of a variable domain of SEQ ID NO:26 and a variable domain of SEQ ID NO: 27.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 22, 2023
From: STAVENHAGEN, JEFFREY B
To: H. LUNDBECK A/S
Reel/Frame 063055/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 18, 2021
From: KALLUNKI, PEKKA; KRISTJANSEN, PAUL E.G.
To: H. LUNDBECK A/S
Reel/Frame 055318/0869 →
Priority Claims (1)
DK PA201600710
· Nov 15, 2016
· national
Continuity (2)
References Cited (337)
US 4179337A
· Davis et al.
· 1979
[cited by applicant]
US 4495285A
· Shimizu et al.
· 1985
[cited by applicant]
US 4609546A
· Hiratani
· 1986
[cited by applicant]
US 4766106A
· Katre et al.
· 1988
[cited by applicant]
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5545806A
· Lonberg et al.
· 1996
[cited by applicant]
US 5545807A
· Surani et al.
· 1996
[cited by applicant]
US 5569825A
· Lonberg et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5625126A
· Lonberg et al.
· 1997
[cited by applicant]
US 5633425A
· Lonberg et al.
· 1997
[cited by applicant]
US 5661016A
· Lonberg et al.
· 1997
[cited by applicant]
US 5741957A
· Doboer et al.
· 1998
[cited by applicant]
US 5750172A
· Meade et al.
· 1998
[cited by applicant]
US 5756687A
· Denman et al.
· 1998
[cited by applicant]
US 5770429A
· Lonberg et al.
· 1998
[cited by applicant]
US 5789650A
· Lonberg et al.
· 1998
[cited by applicant]
US 5814318A
· Lonberg et al.
· 1998
[cited by applicant]
US 5827690A
· Meade et al.
· 1998
[cited by applicant]
US 5859205A
· Adair et al.
· 1999
[cited by applicant]
US 5874299A
· Lonberg et al.
· 1999
[cited by applicant]
US 5877397A
· Lonberg et al.
· 1999
[cited by applicant]
US 6407213B1
· Carter et al.
· 2002
[cited by applicant]
US 6881557B2
· Foote
· 2005
[cited by applicant]
US 8092801B2
· Schenk
· 2012
[cited by examiner]
US 8609820B2
· Saldanha
· 2013
[cited by examiner]
US 8632776B2
· Nordström et al.
· 2014
[cited by applicant]
US 20020197258A1
· Ghanbari et al.
· 2002
[cited by applicant]
US 20060205024A1
· Rogers et al.
· 2006
[cited by applicant]
US 20140186294A1
· Gardai et al.
· 2014
[cited by applicant]
US 20200309796A1
· Malik et al.
· 2020
[cited by applicant]
US 20230312693A1
· Kallunki
· 2023
[cited by examiner]
CL 2011000739A1
· 2011
[cited by applicant]
CL 2018000075A1
· 2018
[cited by applicant]
EP 3067066A1
· 2016
[cited by applicant]
GB 1512203A
· 1974
[cited by applicant]
JP 2008517928A
· 2008
[cited by applicant]
KR 20120090672A
· 2012
[cited by applicant]
WO 8804777A1
· 1988
[cited by applicant]
WO WO9203918A1
· 1992
[cited by applicant]
WO WO9222645A1
· 1992
[cited by applicant]
WO WO9301227A1
· 1993
[cited by applicant]
WO WO9425585A1
· 1994
[cited by applicant]
WO WO9824884A1
· 1998
[cited by applicant]
WO WO0109187A2
· 2001
[cited by applicant]
WO WO0114424A2
· 2001
[cited by applicant]
WO WO0204482A1
· 2002
[cited by applicant]
WO WO0243478A2
· 2002
[cited by applicant]
WO WO2004041067A2
· 2004
[cited by applicant]
WO WO2005013889A2
· 2005
[cited by applicant]
WO 2005047860A2
· 2005
[cited by applicant]
WO WO2006020581A2
· 2006
[cited by applicant]
WO WO2006045037A2
· 2006
[cited by applicant]
WO WO2007011907A2
· 2007
[cited by applicant]
WO WO2007012061A2
· 2007
[cited by applicant]
WO WO2007059782A1
· 2007
[cited by applicant]
WO WO2008103472A2
· 2008
[cited by applicant]
WO WO2009097006A2
· 2009
[cited by applicant]
WO WO2009133521A2
· 2009
[cited by applicant]
WO WO2010039308A1
· 2010
[cited by applicant]
WO 2010118282A1
· 2010
[cited by applicant]
WO WO2011104696A1
· 2011
[cited by applicant]
WO WO2011107544A1
· 2011
[cited by applicant]
WO WO2011147890A1
· 2011
[cited by applicant]
WO WO2012177972A1
· 2012
[cited by applicant]
WO WO2013063516A1
· 2013
[cited by applicant]
WO 2014066318A1
· 2014
[cited by applicant]
WO WO2014132210A1
· 2014
[cited by applicant]
WO WO2015001504A2
· 2015
[cited by applicant]
WO WO2015075011A1
· 2015
[cited by applicant]
WO WO2016061389A2
· 2016
[cited by applicant]
WO 2016179569A1
· 2016
[cited by applicant]
WO 2017009312A1
· 2017
[cited by applicant]
WO WO2017207739A1
· 2017
[cited by applicant]
Kurtz, A. L. et al, Dementia in Parkinson's disease, 2011, Current treatment options in neurology, vol. 13, 242-254. (Year: 2011).
[cited by examiner]
Masliah, E. et al, Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease, 2011, PLoS One, vol. 6, Issue 4, e19338. (Year: 2011).
[cited by examiner]
International Search Report and Written Opinion mailed Nov. 10, 2016 for Application No. PCT/EP2016/066476 .
[cited by applicant]
International Search Report and Written Opinion mailed Mar. 6, 2018 in connection with PCT/EP2017/079153.
[cited by applicant]
International Search Report and Written Opinion mailed Mar. 26, 2018 in connection with PCT/EP2017/083994.
[cited by applicant]
International Search Report and Written Opinion mailed May 2, 2018 in connection with PCT/EP2017/082749.
[cited by applicant]
International Search Report and Written Opinion mailed Mar. 13, 2019 in connection with PCT/EP2018/085898.
[cited by applicant]
[No Author Listed] Wikipedia: Parkinson's disease. 2004; last updated Feb. 21, 2020. Retrieved from the Internet under https://en.wikipedia.org/wiki/Parkinson%27s_disease on Jan. 29, 2020. 39 pages.
[cited by applicant]
[No Author Listed] Wikipedia: Pharmalogical treatment of Parkinson's disease. 2014; last updated: Oct. 1, 2019. Retrieved from the Internet under https://en.wikipedia.org/wiki/Pharmacological_treatment_of_Parkinson%27s_…
[cited by applicant]
[No Author Listed] Wikipedia: Synucleinopathy. 2014; last updated: Aug. 25, 2019. Retrieved from the Internet under https://en.wikipedia.org/wiki/Synucleinopathy on Sep. 23, 2019. 3 pages.
[cited by applicant]
Ahmed et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. May 2014;127(5):66…
[cited by applicant]
Allen et al., Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. Nov. 1, 2002;22(21):9340-51.
[cited by applicant]
Altschul, Amino acid substitution matrices from an information theoretic perspective. J Mol Biol. Jun. 5, 1991;219(3):555-65.
[cited by applicant]
Aslanidis et al., Ligation-independent cloning of PCR products (LIC-PCR). Nucleic Acids Res. Oct. 25, 1990;18(20):6069-74.
[cited by applicant]
Bae et al., Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. Sep. 26, 2012;32(39):13454-69.
[cited by applicant]
Barderas et al.,Affinity Maturation of Antibodies Assisted by in Silico Modeling. Proc. Natl. Acad. Sci. (USA)2008;105(26):9029-9034.
[cited by applicant]
Bassil et al., Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci U S A. Aug. 23, 2016;113(34):9593-8. doi: 10.1073/pnas.1…
[cited by applicant]
Besong-Agbo et al., Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology. Jan. 8, 2013;80(2):169-75. doi: 10.1212/WNL.0b013e31827b90d1. Epub Dec. 19, 2012.
[cited by applicant]
Beyer et al., α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol. Apr. 2013;47(2):509-24. doi: 10.1007/s12035-012-8330-5. Epub Aug. 25, 2012.
[cited by applicant]
Bird et al., Single-chain antigen-binding proteins. Science. Oct. 21, 1988; 242:423-6.
[cited by applicant]
Bostrom et al., Improving Antibody Binding Affinity and Specificity for Therapeutic Development. Methods Mol. Biol. 2009;525:353-376.
[cited by applicant]
Braak et al., Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3-12.
[cited by applicant]
Braak et al., Neuropathology of Alzheimer's disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 3:14-22.
[cited by applicant]
Breteler et al., A community-based study of dementia: the Rotterdam Elderly Study. Neuroepidemiology. 1992;11 Suppl 1:23-8.
[cited by applicant]
Carter et al., Humanization of an Anti-p185her2 Antibody for Human Cancer Therapy. Proc. Natl. Acad. Sci. (U.S.A.) May 1992; 89:4285-4289.
[cited by applicant]
Chen et al., Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion. International Immunology. 1993;5(6):647-656.
[cited by applicant]
Chen et al., B cell development in mice that lack one or both immunoglobulin kappa light chain genes. EMBO J. Mar. 1993;12(3):821-30.
[cited by applicant]
Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. Jun. 15, 1995;14(12):2784-94.
[cited by applicant]
Chothia et al., Canonical structures for the Hypervariable domains of Immunoglobulins. J. Mol. Biol. (1987) 196, 901-917.
[cited by applicant]
Clackson et al., Making antibody fragments using phage display libraries. Nature. 1991;352:624-628.
[cited by applicant]
Clavaguera et al., Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A. Jun. 4, 2013;110(23):9535-40. doi: 10.1073/pnas.1301175110. Epub May 20, 2013.
[cited by applicant]
Clavaguera et al., Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. Feb. 2014; 127(2):299-301. doi: 10.1007/s00401-013-1231-5. Epub Dec. 21, 2013.
[cited by applicant]
Clavaguera et al., Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. Jul. 2009; 11(7):909-13. doi: 10.1038/ncb1901. Epub Jun. 7, 2009.
[cited by applicant]
Co et al., Chimeric and Humanized Antibodies With Specificity for the CD33 Antigen. J. Immunol. 1992; 148:1149-1154.
[cited by applicant]
Co et al., Humanized Antibodies for Antiviral Therapy. Proc. Natl. Acad. Sci. (U.S.A.) (1991) 88:2869-2.
[cited by applicant]
Conway et al., Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad…
[cited by applicant]
Crary et al., Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. Dec. 2014;128(6):755-66. doi: 10.1007/s00401-014-1349-0. Epub Oct. 28, 2014.
[cited by applicant]
Czapski et al., Extracellular alpha-synuclein induces calpain-dependent overactivation of cyclin-dependent kinase 5 in vitro. FEBS Lett. Sep. 17, 2013;587(18):3135-41.
[cited by applicant]
Daher et al., Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem. Aug. 7, 2015;290(32):19433-44. doi: 10.1074/jbc.M115.660001. Epub Jun. 15, 20…
[cited by applicant]
Dehay et al., Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. Aug. 2015;14(8):855-866. Epub Jun. 3, 2015.
[cited by applicant]
Derkinderen et al., Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord. Jul. 2014;29(8):976-9.
[cited by applicant]
Di Scala et al., Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and a-synuclein. Sci Rep. Jun. 29, 2016;6:28781. doi: 10.1038/srep28781.
[cited by applicant]
Dufty et al., Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol. May 2007;170(5):1725-38.
[cited by applicant]
Dumont et al., Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. Dec. 2016;36(6):1110-1122. Epub Sep. 18, 2015. Review.
[cited by applicant]
Eddy, Where Did the BLOSUM62 Alignment Score Matrix Come From? Nature Biotech. 2004;22(8):1035-1036.
[cited by applicant]
Elgert, Chapter 4:“Antibody Structure and Function.” Immunology: Understanding the Immune System. John Wiley & Sons, Inc. 1998; p. 58-78.
[cited by applicant]
Elvang et al., Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem. Sep. 2009;110(5):1377-87. doi: 10.1111/j.1471-4159.2009.06215.x. Epub Jun. 10, 2009.
[cited by applicant]
Emadi et al., Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol. May 11, 2007;368(4):1132-44. Epub…
[cited by applicant]
Emanuele et al., Exogenous Alpha-Synuclein Alters Pre- and Post-Synaptic Activity by Fragmenting Lipid Rafts. EBioMedicine. May 2016;7:191-204. doi: 10.1016/j.ebiom.2016.03.038. Epub Apr. 5, 2016.
[cited by applicant]
Evans et al., Rapid expression of an anti-human C5 chimeric Fab utilizing a vector that replicates in COS and 293 cells. J Immunol Methods. Jul. 17, 1995;184(1):123-38.
[cited by applicant]
Finlay et al., Affinity Maturation of a Humanized Rat Antibody for Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals a High Level of Mutational Plasticity Both Inside and Outside the Complementarity-Determining Regio…
[cited by applicant]
Fishwild et al., High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol. Jul. 1996;14(7):845-51.
[cited by applicant]
Fleming et al., Behavioral phentoypes and pharmacology in genetic mouse models of Parkinsonism. Behav Pharmacol. Sep. 2006;17(5-6):383-91.
[cited by applicant]
Foote et al., Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol. Mar. 20, 1992;224(2):487-99.
[cited by applicant]
Galasko et al., Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol. Sep. 1994;51(9):888-95.
[cited by applicant]
Galpern et al., Interface between tauopathies and synucleinopathies: a tale of two proteins. Mar. 2006;59(3):449-58.
[cited by applicant]
Games et al., Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein. Am J Pathol. Mar. 2013;182(3):940-53. doi: 10.1016/j.ajpath…
[cited by applicant]
Games et al., Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci. Jul. 9, 2014;34(28):9441-54.
[cited by applicant]
Gardai et al., Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One. Aug. 23, 2013;8(8):e71634. doi: 10.1371/journal.pone.0071634. …
[cited by applicant]
Giasson et al., Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. Apr. 25, 2003;300(5619):636-40.
[cited by applicant]
Glaser et al. Antibody engineering by codon-based mutagenesis in a filamentous phage vector system. J Immunol. Dec. 15, 1992;149(12):3903-13.
[cited by applicant]
Gonzales et al., SDR Grafting of a Murine Antibody Using Multiple Human Germline Templates to Minimize Its Immunogenicity. Mol. Immunol. 2004;41:863-872.
[cited by applicant]
Gorman et al., Reshaping a Therapeutic CD4 Antibody. Proc. Natl. Acad. Sci. (U.S.A.) May 1991;88:4181-4185.
[cited by applicant]
Gruden et al., Correlation between protective immunity to α-synuclein aggregates, oxidative stress and inflammation. Neuroimmunomodulation. 2012;19(6):334-42. doi: 10.1159/000341400. Epub Sep. 11, 2012.
[cited by applicant]
Gruden et al., Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression. J Neuroimmunol. Apr. 2011;233(1-2):221-7.
[cited by applicant]
Guerrero-Muñoz et al., Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiol Dis. Nov. 2014;71:14-23. doi: 10.1016/j.nbd.2014.08.008. Epub Aug. 15, 2014.
[cited by applicant]
Guilliams et al., Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. J Mol Biol. Jul. 24, 2013;425(14):2397-411. doi: 10.1016/j.jmb.2013.01.040. Epub Apr. 1, 2013.
[cited by applicant]
Gunasekaran et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects. JBC;2010:285(25):19637-46.
[cited by applicant]
Guo el at., Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell. Jul. 3, 2013;154(1):103-17. doi: 10.1016/j.cell.2013.05.057.
[cited by applicant]
Gustchina et al., Affinity Maturation by Targeted Diversification of the CDR-H2 Loop of a Monoclonal Fab Derived From a Synthetic Naïve Human Antibody Library and Directed Against the Internal Trimeric Coiled-Coil of Gp…
[cited by applicant]
Hackel et al., Stability and CDR Composition Biases Enrich Binder Functionality Landscapes. J. Mol. Biol. 2010;401(1):84-96.
[cited by applicant]
Hall et al. Behavioural deficits in transgenic mice expressing human truncated (1-120 amino acid) alpha-synuclein. Exp Neurol. Feb. 2015;264:8-13. doi: 10.1016/j.expneurol.2014.11.003. Epub Nov. 20, 2014.
[cited by applicant]
Hansen et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. Feb. 2011;121(2):715-25. doi: 10.1172/JCI43366. Epub Jan. 18, 2011.
[cited by applicant]
Hansen et al., Beyond α-synuclein transfer: pathology propagation in Parkinson's disease. Trends Mol Med. May 2012;18(5):248-55. doi: 10.1016/j.molmed.2012.03.002. Epub Apr. 13, 2012. Review.
[cited by applicant]
Harding et al., Class switching in human immunoglobulin transgenic mice. Ann. N. Y. Acad. Sci. 1995;764:536-546.
[cited by applicant]
He et al., Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model. Eur J Neurosci. Jan. 2016;43(1):41-52. doi: 1…
[cited by applicant]
Henikoff et al., Amino acid substitution matrices from protein blocks. Proc. Natl. Acad. Sci. (USA). Nov. 1992;89:10915-10919.
[cited by applicant]
Hepp et al., Distribution and load of amyloid-β pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol. Oct. 2016;75(10):936-945.
[cited by applicant]
Holliger et al., “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. Jul. 15, 1993;90(14):6444-8.
[cited by applicant]
Holmes et al., Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. Oct. 14, 2014;111(41):E4376-85. doi: 10.1073/pnas.1411649111. Epub Sep. 26, 2014.
[cited by applicant]
Holt et al., Domain antibodies: proteins for therapy. Trends Biotechnol. Nov. 2003;21(11):484-90.
[cited by applicant]
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in
[cited by applicant]
Jack et al., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. Feb. 2013;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0. Author manuscrip…
[cited by applicant]
Jakes et al., Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. Neurosci Lett. Jul. 2, 1999;269(1):13-6.
[cited by applicant]
Jellinger, Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord. Jan. 2012;27(1):8-30.
[cited by applicant]
Kabiraj et al., An 11-mer Amyloid Beta Peptide Fragment Provokes Chemical Mutations and Parkinsonian Biomarker Aggregation in Dopaminergic Cells: A Novel Road Map for “Transfected” Parkinson's. ACS Chem Neurosci. Nov. 1…
[cited by applicant]
Karlin et al., Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes. Proc. Natl. Acad. Sci. (USA). 1990;87:2264-2268.
[cited by applicant]
Kellie et al., Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by mass spectrometry. Sci Rep. Jul. 23, 2014;4:5797. doi: 10.1038/srep05797.
[cited by applicant]
Kettleborough et al., Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: The Importance of Framework Residues on Loop Conformation. Protein Engineering. 1991;4:773-3783.
[cited by applicant]
Kim et al., Hypoestoxide reduces neuroinflammation and a-synuclein accumulation in a mouse model of Parkinson's disease. J Neuroinflammation. Dec. 18, 2015;12:236. doi: 10.1186/s12974-015-0455-9.
[cited by applicant]
Kim et al., Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol. Jun. 2016;25(3):113-9. doi: 10.5607/en.2016.25.3.113. Epub Jun. 8, 2016.
[cited by applicant]
Kirik et al., Modeling CNS neurdegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci. Jul. 2003;26(7):386-92.
[cited by applicant]
Kirik et al., Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci. Apr. 1, 2002;22(7):2780-91.
[cited by applicant]
Koehler et al., Altered serum IgG levels to a-synuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One. May 31, 2013;8(5):e64649. doi: 10.1371/journal.pone.0064649. Print 2013.
[cited by applicant]
Köhler et al., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. Aug. 7, 1975;256(5517):495-7.
[cited by applicant]
Krause et al., An Insertion Mutation That Distorts Antibody Binding Site Architecture Enhances Function of a Human Antibody. MBio. Feb. 8, 2011;2(1):e00345-10. doi: 10.1128/mBio.00345-10.
[cited by applicant]
Kruger et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. Feb. 1998;18(2):106-8.
[cited by applicant]
Kuan et al., Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer. Jul. 1, 2011;129(1):111-21. doi: 10.1002/ijc.25645. Epub Nov. 3, 2010.
[cited by applicant]
Labrijn et al., Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A. Mar. 26, 2013;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub Mar. 11, 2013.
[cited by applicant]
Lambert et al., Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. Dec. 2013;45(12):1452-8. doi: 10.1038/ng.2802. Epub Oct. 27, 2013. Author manuscript.
[cited by applicant]
Launer, Overview of incidence studies of dementia conducted in Europe. Neuroepidemiology. 1992;11 Suppl 1:2-13.
[cited by applicant]
Lee et al., Extracellular β—synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol. Feb. 2014;10(2):92-8. doi: 10.1038/nrneurol.2013.275. Epub Jan. 28, 2014. Review.
[cited by applicant]
Lee et al., Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. Oct. 5, 2006;52(1):33-8. Review.
[cited by applicant]
Lindstrom et al., Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis. Sep. 2014;69:134-43. doi: 10.1016/j.nbd.2014.05.009. Epub May 20, 2014.
[cited by applicant]
Lobuglio et al.,Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response. Proc. Natl. Acad. Sci. (U.S.A.). 1989 86:4220-4224.
[cited by applicant]
Loiodice et al., Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications. Psychopharmacology (Berl). Jan. 2017;234(1):15-27. doi: 10.1007…
[cited by applicant]
Lonberg et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature. Apr. 28, 1994;368(6474):856-9.
[cited by applicant]
Lonberg et al., Human antibodies from transgenic mice. Intern. Rev. Immunol. 1995;13:65-93.
[cited by applicant]
Lorenzo et al. Prediction of Spontaneous Protein Deamidation from Sequence-Derived Secondary Structure and Intrinsic Disorder. PLoS One. Dec. 16, 2015;10(12):e0145186. doi: 10.1371/journal.pone.0145186. eCollection 2015.
[cited by applicant]
Luk et al., Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-nucleinopathy in mice. J Exp Med. May 7, 2012;209(5):975-86. doi: 10.1084/jem.20112457. Epub Apr. 16,…
[cited by applicant]
Luk et al., Pathological α-Synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. Nov. 16, 2012;338(6109):949-53.
[cited by applicant]
Luo et al., Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients. Exp Ther Med. Sep. 2016;12(3):1373-1376. Epub Jun. 21, 2016.
[cited by applicant]
Ma et al., Advances with microRNAs in Parkinson's disease research. Drug Des Devel Ther. Oct. 1, 2013;7:1103-13. doi: 10.2147/DDDT.S48500. eCollection 2013.
[cited by applicant]
Mabry et al., Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Peds. 2010;23(3):115-127.
[cited by applicant]
Maeda et al., Construction of Reshaped Human Antibodies With HIV-Neutralizing Activity. Human Antibodies Hybridoma. 1991;2:124-34.
[cited by applicant]
Maetzler et al., Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. PLoS One. Feb. 21, 2014;9(2):e88604. doi: 10.1371/journal.pone.00…
[cited by applicant]
Mahowald et al., When and where do synucleinopathies begin? Neurology (2010) 75:488-489.
[cited by applicant]
Maingay et al., Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. CNS Spectr. Mar. 2005;10(3):235-44. Review.
[cited by applicant]
Mao et al., Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. Sep. 30, 2016;353(6307). pii: aah3374.
[cited by applicant]
Marks et al., By-passing immunization human antibodies from V-gene libraries displayed on phage. J. MoI. Biol. 1991;222: 581-597.
[cited by applicant]
Mazzulli et al., Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. J Neurosci. Jul. 20, 2016;36(29):7693-706. doi: 10.1523/JNEUR…
[cited by applicant]
McCafferty et al., Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348:552-4.
[cited by applicant]
McKeith et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology (1996) 47:1113-24.
[cited by applicant]
Metz et al., Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel. Oct. 2012;25(10):571-80. Epub Sep. 13, 2012.
[cited by applicant]
Mishizen-Eberz et al., Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry. 2005;44:7818-29.
[cited by applicant]
Mishizen-Eberz et al., Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem. Aug. 2003;86(4):836-47.
[cited by applicant]
Montgomery et al., Affinity Maturation and Characterization of a Human Monoclonal Antibody Against HIV-1 gp41. Mabs. 2009; 1(5):462-474.
[cited by applicant]
Moore et al., A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. Mabs. 2011;3(6):546-557.
[cited by applicant]
Nelson et al., Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. May 2012;71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7.
[cited by applicant]
Nemani et al., Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. Jan. 14, 2010;65(1):66-79. doi: 10.1016/j.neuron.2009.12.023.
[cited by applicant]
Oikawa et al., α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly. J Biol Chem. Jul. 15, 2016;291(29):15046-56. doi: 10.1074/jbc.M116.736355. Epub May 19, 2…
[cited by applicant]
Pacheco et al., Extracellular α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J Neurochem. Mar. 2015;132(6):731-41. doi: 10.1111/jnc.13060. Epub Feb. 25, 2015.
[cited by applicant]
Papachroni et al., Autoantibodies to alpha-synuclein in inherited Parkison's disease. J Neurochem. May 2007;101(3):749-56.
[cited by applicant]
Paumier et al., Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One. Aug. 1, 2013;8(8):e70274. doi: 10.1371/journal.pone.0070274. Print 2013.
[cited by applicant]
Peelaerts et al., α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. Jun. 18, 2015;522(7556):340-4. doi: 10.1038/nature14547. Epub Jun. 10, 2015.
[cited by applicant]
Polymeropoulos et al., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. Jun. 27, 1997;276(5321):2045-7.
[cited by applicant]
Probst et al., Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. May 2000;99(5):469-81.
[cited by applicant]
Recasens et al., Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. Mar. 2014;75(3):351-62. doi: 10.1002/ana.24066. First published Nov.…
[cited by applicant]
Reglodi et al., Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol. Aug. 2017; 155:120-148. doi: 10.1016/j.pneurobio.2015.10.004. Epub Nov. 2, 20…
[cited by applicant]
Revets et al., Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther. 2005; 5(1):111-24. DOI: 10.1517/14712598.5.1.111.
[cited by applicant]
Ridgway et al., ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. Jul. 1996;9(7):617-21.
[cited by applicant]
Riechmann et al., Reshaping Human Antibodies for Therapy. Nature. 1988;332:323-327.
[cited by applicant]
Ritchie et al., Alpha-synuclein truncation and disease. Health. 2012;4(Special Issue):1167-1177.
[cited by applicant]
Rudikoff et al., Single Amino Acid Substitution Altering Antigen-Binding Specificity. Proc. Natl. Acad. Sci. (USA). 1982;79(6):1979-1983.
[cited by applicant]
Sahara et al., Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain. J Alzheimers Dis. 2013;33(1):249-63. doi: 10.3233/JAD-2012-121093. Author manuscript.
[cited by applicant]
Sato et al., Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. Feb. 15, 1993;53(4):851-6.
[cited by applicant]
Schelle et al., Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement. Jun. 2017; 13(6):701-709. doi: 10.1016/j.jalz.2016.09.005. Epub…
[cited by applicant]
Schier et al., Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. Nov. 8, 1996;263(4):…
[cited by applicant]
Shahaduzzaman et al., Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease. PLoS One. Feb…
[cited by applicant]
Smith et al., α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls. PLoS One. 2012;7(12):e52285. doi: 10.1371/journal.pone.0…
[cited by applicant]
Spencer et al., ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther. Oct. 2014;22(10):1753-67. doi: 10.1038/mt.2014.129. Epub Jul.…
[cited by applicant]
Spencer et al., Reducing Endogenous a-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci. Jul. 2, 20167;36(30):7971-84. doi:10.1523/JNEURO…
[cited by applicant]
Spillantini et al., Alpha-synuclein in Lewy bodies. Nature. Aug. 28, 1997;388(6645):839-40.
[cited by applicant]
Spreter Von Kreudenstein et al., Improving biophysical properties of a bispecific antibody scaffold to aid developability. Mabs. 2013;5(5):646-654.
[cited by applicant]
Springer et al., Mechanisms and models of α-synuclein-related neurodegeneration. Curr Neurol Neurosci Rep. Sep. 2006;6(5):432-6.
[cited by applicant]
Steidl et al., In Vitro Affinity Maturation of Human GM-CSF Antibodies by Targeted CDR-Diversification. 2008 Mol. Immunol. 46(1):135-144.
[cited by applicant]
Strop et al., Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. JMB. 2012;420:204-219.
[cited by applicant]
Surmeier et al., Calcium and Parkinson's disease. Biochem Biophys Res Commun. Feb. 19, 2017;483(4):1013-1019. doi: 10.1016/j.bbrc.2016.08.168. Epub Aug. 30, 2016. Review.
[cited by applicant]
Takeda et al., Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol. Feb. 1998;152(2):367-72.
[cited by applicant]
Tavassoly et al., The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease. Eur J Med Chem. Dec. 17, 2014;88:42-54. doi: 10.1016/j.ejmech.2014.07.090. Epub Jul. 2…
[cited by applicant]
Taylor et al., L. et al., Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM. Int Immunol. Apr. 1994;6(4):579-91.
[cited by applicant]
Taylor et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Res. Dec. 11, 1992;20(23):6287-95.
[cited by applicant]
Tempest et al., Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in vivo. Bio/Technology. 1991; 9:266-271.
[cited by applicant]
Tofaris et al., Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci…
[cited by applicant]
Tóth et al., Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS One. Feb. 14, 2014;9(2):e87133. doi: 10.1371/jo…
[cited by applicant]
Tran et al., A-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. Jun. 26, 2014;7(6):2054-65. doi: 10.1016/j.celrep.2014.05.033. Epub Jun. 12, 2014.
[cited by applicant]
Tuaillon et al., Biased utilization of DHQ52 and JH4 gene segments in a human Ig transgenic minilocus is independent of antigenic selection. J Immunol. Mar. 15, 1994;152(6):2912-20.
[cited by applicant]
Ulusoy et al., Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci. Aug. 2010;32(3):409-22. doi: 10.1111/j.1460-9568.2010.07284.x.
[cited by applicant]
Vaikath et al., Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiol Dis. Jul. 2015;79:81-99. doi: 10.1016/j.nbd.2015.04.009. Epub Apr. 30, 2015.
[cited by applicant]
Valera et al., Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther. Jun. 2013;138(3):311-22. doi: 10.1016/j.pharmthera.2013.01.013. Epub Feb. 4, 2013. Author manuscript.
[cited by applicant]
Vekrellis et al., Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. Nov. 2011;10(11):1015-25.
[cited by applicant]
Verhoeyen et al., Reshaping Human Antibodies: Grafting an Antilysozyme Activity. Science. 1988. 239:1534-1536.
[cited by applicant]
Volles et al., Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease. J. Biochem. 42:7871-7878, 2003.
[cited by applicant]
Volpicelli-Daley et al., Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. Oct. 6, 2011;72(1):57-71. doi: 10.1016/j.neuron.2011.08.033.
[cited by applicant]
Wakabayashi et al., NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett. Dec. 12, 1997;239(1):45-8.
[cited by applicant]
Wakamatsu et al.,Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol Aging. Apr. 2008;29(4):574-85. Epub Dec. 14, 2006.
[cited by applicant]
Walker et al., Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. Mar. 1, 2013;70(3):304-10.
[cited by applicant]
Wang et al., Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein. Proc Natl Acad Sci U S A. Aug. 23, 2016;113(34):9587-92. doi: 10.1073/pnas.1610099113. Epub Aug. 1, 201…
[cited by applicant]
Ward et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Waxman et al., Induction of intracellular tau aggregation is promoted by a-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. May 25, 2011;31(21):7604-18. doi: 10.1523/JNEUROSC…
[cited by applicant]
Weiner et al., Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. Jul. 2015;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005. Author manuscript.
[cited by applicant]
Westerlund et al., Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol Cell Neurosci. Dec. 2008;39(4):586-91. doi: 10.1016/j.men.2008.08.001. Epub Aug. 27, 2008.
[cited by applicant]
Woerman et al., Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci U S A. Sep. 1, 2015;112(35):E4949-58. doi: 10.1073/pnas.1513426112. Epub Aug. 18, 2015.
[cited by applicant]
Woulfe et al., Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology. May 14, 2002;58(9):1435-6.
[cited by applicant]
Wrasidlo et al., A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain. Dec. 2016;139(Pt 12):3217-3236. Epub Sep. 27, 2016.
[cited by applicant]
Wu et al., Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci U S A. May 26, 1998;95(11):6037-42.
[cited by applicant]
Xu et al., CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human f…
[cited by applicant]
Xu et al., Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease. Neurochem Res. Oct. 2016;41(10):2788-2796. Epub Jun. 30, 2016.
[cited by applicant]
Yamada, Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology. Dec. 2003;23(4):311-7. Abstract only.
[cited by applicant]
Yanamandra et al., Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. Oct. 16, 2013;80(2):402-414. doi: 10.1016/j.neuron.2013.07.046. Epub Se…
[cited by applicant]
Yanamandra et al., α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One. Apr. 25, 2011;6(4):e18513. doi: 10.1371/journal.pone.0018513.
[cited by applicant]
Yap et al., Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem. Aug. 12, 2011;286(32):28080-8. doi: 10.1074/jbc.M111.237859. Epub Jun. 8, 201…
[cited by applicant]
Yap et al., Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab. Jan. 2013;108(1):56-64. doi: 10.1016/j.ymgme.2012.11.010. Epub Nov. 28, 2012.
[cited by applicant]
Yelton et al., Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol. Aug. 15, 1995;155(4):1994-2004.
[cited by applicant]
Zhao et al., AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson's disease diagnosis. Protein Cell. Sep. 2017;8(9):696-700.
[cited by applicant]
Zou et al., Gene targeting in the Ig kappa locus: efficient generation of lambda chain-expressing B cells, independent of gene rearrangements in Ig kappa. EMBO J. Mar. 1993;12(3):811-20.
[cited by applicant]
Chartier-Harlin et al., Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. Sep. 25-Oct. 1, 2004;364(9440):1167-9.
[cited by applicant]
Connolly et al., Pharmacological treatment of parkinson disease: a review. JAMA. Apr. 23-30, 2014;311(16):1670-83.
[cited by applicant]
Goldman et al., Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. Feb. 2018;33(2):282-288. Epub Dec. 4, 2017.
[cited by applicant]
Harding et al., Class switching in human immunoglobulin transgenic mice. Ann N Y Acad Sci. Sep. 29, 1995;764:536-46.
[cited by applicant]
Kussie et al., A single engineered amino acid substitution changes antibody fine specificity. J Immunol. Jan. 1, 1994;152(1):146-52.
[cited by applicant]
Majbour et al., Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener. Jan. 19, 2016;11:7.
[cited by applicant]
Polymeropoulos M.H., Autosomal dominant parkinson's disease and alpha-synuclein. Ann Neurol. Sep. 1998;44(3 Suppl 1):S63-4.
[cited by applicant]
Scott et al., Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14. Epub May 1, 2012.
[cited by applicant]
Simonsen et al., The utility of a-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. Biomark Med. 2016;10(1):19-34. Epub Aug. 28, 2015.
[cited by applicant]
Singleton et al., alpha-Synuclein locus triplication causes Parkinson's disease. Science. Oct. 31, 2003;302(5646):841.
[cited by applicant]
Zarranz et al., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. Feb. 2004;55(2):164-73.
[cited by applicant]
U.S. Appl. No. 15/207,859, filed Jul. 12, 2016, Granted, U.S. Pat. No. 10,800,836.
[cited by applicant]
U.S. Appl. No. 15/812,251, filed Nov. 14, 2017, Granted, U.S. Pat. No. 10,358,482.
[cited by applicant]
U.S. Appl. No. 15/812,303, filed Nov. 14, 2017, Granted, U.S. Pat. No. 10,358,483.
[cited by applicant]
U.S. Appl. No. 15/812,363, filed Nov. 14, 2017, Granted, U.S. Pat. No. 10,364,285.
[cited by applicant]
U.S. Appl. No. 15/812,410, filed Nov. 14, 2017, Granted, U.S. Pat. No. 10,358,484.
[cited by applicant]
U.S. Appl. No. 15/812,648, filed Nov. 14, 2017, Granted, U.S. Pat. No. 10,889,635.
[cited by applicant]
U.S. Appl. No. 15/848,999, filed Dec. 20, 2017, Granted, U.S. Pat. No. 10,364,286.
[cited by applicant]
U.S. Appl. No. 16/469,482, filed Jun. 13, 2019, Allowed, 2020-0024337.
[cited by applicant]
Degorce et al., HTRF: A technology tailored for drug discovery—a review of theoretical aspects and recent applications. Curr Chem Genomics. May 28, 2009;3:22-32. doi: 10.2174/1875397300903010022.
[cited by applicant]
Bardelli et al., Epitope mapping by solution NMR spectroscopy. J Mol Recognit. Jun. 2015;28(6):393-400. doi: 10.1002/jmr.2454. Epub Feb. 27, 2015.
[cited by applicant]
Simonyan et al., Conformational epitope mapping by cross-link mass spectrometry: Analysis of Ipilimumab, Nivolumab, and Pembrolizumab. CovalX. Nov. 15, 2017. Retrieved on Jun. 3, 2019 from: https://www.amr-inc.co.jp/dcm…
[cited by applicant]